NASDAQ:KMDA Kamada (KMDA) Stock Price, News & Analysis $6.50 +0.15 (+2.36%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$6.50 0.00 (0.00%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kamada Stock (NASDAQ:KMDA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kamada alerts:Sign Up Key Stats Today's Range$6.40▼$6.5750-Day Range$5.76▼$8.0952-Week Range$4.74▼$9.16Volume97,478 shsAverage Volume85,107 shsMarket Capitalization$373.62 millionP/E Ratio23.21Dividend YieldN/APrice Target$14.67Consensus RatingBuy Company OverviewKamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.Read More… Kamada Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks77th Percentile Overall ScoreKMDA MarketRank™: Kamada scored higher than 77% of companies evaluated by MarketBeat, and ranked 276th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingKamada has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKamada has only been the subject of 2 research reports in the past 90 days.Read more about Kamada's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth39.13% Earnings GrowthEarnings for Kamada are expected to grow by 39.13% in the coming year, from $0.23 to $0.32 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kamada is 23.21, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 21.40.Price to Earnings Ratio vs. SectorThe P/E ratio of Kamada is 23.21, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 21.94.Price to Earnings Growth RatioKamada has a PEG Ratio of 0.97. PEG Ratios around 1 indicate that a company is correctly valued.Price to Book Value per Share RatioKamada has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Kamada's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.11% of the float of Kamada has been sold short.Short Interest Ratio / Days to CoverKamada has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kamada has recently decreased by 39.79%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKamada does not currently pay a dividend.Dividend GrowthKamada does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.11% of the float of Kamada has been sold short.Short Interest Ratio / Days to CoverKamada has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kamada has recently decreased by 39.79%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News Sentiment0.72 News SentimentKamada has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Kamada this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 3 people have added Kamada to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kamada insiders have not sold or bought any company stock.Percentage Held by Insiders36.10% of the stock of Kamada is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 20.38% of the stock of Kamada is held by institutions.Read more about Kamada's insider trading history. Receive KMDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter. Email Address KMDA Stock News HeadlinesEQS-News: Kamada Is Bringing Relief To Those With Rare And Serious ConditionsApril 17 at 2:30 PM | markets.businessinsider.comKamada Ekadashi Vrat Parana To Be Observed Tomorrow – Know The Timing, Rituals, And MoreApril 9, 2025 | msn.comTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 19, 2025 | Porter & Company (Ad)Perform These Remedies As Per Your Zodiac Sign On Kamada Ekadashi To Please Lakshmi-NarayanApril 8, 2025 | msn.comWhen Is Kamada Ekadashi 2025? Check Auspicious Donations And What To Avoid For Maximum Blessings From Lord VishnuApril 8, 2025 | msn.comKamada Ekadashi 2025: Date, Parana Time, Puja Rituals and SignificanceApril 7, 2025 | msn.comWhy Is Kanta Or Kamada Ekadashi So Special? Find Out hereApril 7, 2025 | msn.comKamada provides update on withholding tax procedures on special cash dividendMarch 24, 2025 | markets.businessinsider.comSee More Headlines KMDA Stock Analysis - Frequently Asked Questions How have KMDA shares performed this year? Kamada's stock was trading at $6.09 at the beginning of 2025. Since then, KMDA shares have increased by 6.7% and is now trading at $6.50. View the best growth stocks for 2025 here. How were Kamada's earnings last quarter? Kamada Ltd. (NASDAQ:KMDA) posted its quarterly earnings data on Wednesday, August, 16th. The biotechnology company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.02 by $0.02. The biotechnology company earned $37.44 million during the quarter, compared to analysts' expectations of $34.18 million. Kamada had a trailing twelve-month return on equity of 6.30% and a net margin of 9.92%. Read the conference call transcript. How do I buy shares of Kamada? Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kamada own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kamada investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), NVIDIA (NVDA), Chipotle Mexican Grill (CMG), ASML (ASML) and Oracle (ORCL). Company Calendar Last Earnings8/16/2023Record date for 4/7 Dividend3/17/2025Ex-Dividend for 4/7 Dividend3/17/2025Dividend Payable4/07/2025Today4/19/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KMDA CIK1567529 Webwww.kamada.com Phone(728) 940-6472Fax972-8940-6473Employees360Year FoundedN/APrice Target and Rating Average Stock Price Target$14.67 High Stock Price Target$18.00 Low Stock Price Target$11.00 Potential Upside/Downside+125.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$0.26 Trailing P/E Ratio23.21 Forward P/E Ratio28.26 P/E Growth0.97Net Income$8.28 million Net Margins9.92% Pretax Margin10.04% Return on Equity6.30% Return on Assets4.49% Debt Debt-to-Equity RatioN/A Current Ratio4.84 Quick Ratio2.73 Sales & Book Value Annual Sales$160.95 million Price / Sales2.32 Cash Flow$0.36 per share Price / Cash Flow17.90 Book Value$4.25 per share Price / Book1.53Miscellaneous Outstanding Shares57,480,000Free Float36,730,000Market Cap$373.62 million OptionableOptionable Beta1.07 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:KMDA) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kamada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.